[HTML][HTML] Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal …
JL González-Larriba, M Lázaro-Quintela… - Translational Lung …, 2017 - ncbi.nlm.nih.gov
One of the most important advances in the treatment of non-small cell lung cancer (NSCLC)
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …
[HTML][HTML] Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal …
JL González-Larriba, M Lázaro-Quintela… - Translational Lung …, 2017 - tlcr.amegroups.org
One of the most important advances in the treatment of non-small cell lung cancer (NSCLC)
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …
Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor …
JL González-Larriba, M Lázaro-Quintela… - Translational Lung …, 2017 - europepmc.org
One of the most important advances in the treatment of non-small cell lung cancer (NSCLC)
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …
[PDF][PDF] Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth …
JL González-Larriba, M Lázaro-Quintela, M Cobo… - seom.org
One of the most important advances in the treatment of non-small cell lung cancer (NSCLC)
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …
Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor …
JL González-Larriba - 2017 - ddd.uab.cat
One of the most important advances in the treatment of non-small cell lung cancer (NSCLC)
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …
[PDF][PDF] Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth …
JL González-Larriba, M Lázaro-Quintela, M Cobo… - cdn.amegroups.cn
One of the most important advances in the treatment of non-small cell lung cancer (NSCLC)
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …
[引用][C] Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth …
JL González-Larriba… - … positive non-small …, 2017 - produccioncientifica.ucm.es
Clinical management of epidermal growth factor receptor mutation-positive non-small cell
lung cancer patients after progression on previous epidermal growth factor receptor tyrosine …
lung cancer patients after progression on previous epidermal growth factor receptor tyrosine …
[PDF][PDF] Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth …
JL González-Larriba, M Lázaro-Quintela, M Cobo… - seom.org
One of the most important advances in the treatment of non-small cell lung cancer (NSCLC)
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …
Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor …
JL González-Larriba… - Translational lung …, 2017 - pubmed.ncbi.nlm.nih.gov
One of the most important advances in the treatment of non-small cell lung cancer (NSCLC)
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …
Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor …
JL González-Larriba, M Lázaro-Quintela… - Translational Lung …, 2017 - tlcr.amegroups.org
One of the most important advances in the treatment of non-small cell lung cancer (NSCLC)
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …
has been the identification of molecular alterations vulnerable to targeted inhibition, such as …